Janus kinase inhibitors in immunoinflammatory rheumatic diseases
Despite great advances in the diagnosis and treatment of immunoinflammatory rheumatic diseases, which have led to a significant improvement in the prognosis in many patients, the fundamental medical problems of this pathology the restoration of the quality of life and the reduction of mortality to...
Main Author: | Evgeny L. Nasonov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
"Consilium Medicum" Publishing house
2022-06-01
|
Series: | Терапевтический архив |
Subjects: | |
Online Access: | https://ter-arkhiv.ru/0040-3660/article/viewFile/108773/82885 |
Similar Items
-
The role of NETosis in the pathogenesis of immunoinflammatory rheumatic diseases
by: E. L. Nasonov, et al.
Published: (2023-10-01) -
Safety of COVID-19 vaccines in patients with immunoinflammatory rheumatic diseases (preliminary data)
by: A. N. Kulikov, et al.
Published: (2022-02-01) -
IMMUNOINFLAMMATORY RHEUMATIC DISEASES ASSOCIATED WITH TYPE I INTERFERON: NEW EVIDENCE
by: E. L. Nasonov, et al.
Published: (2019-09-01) -
Shared features of pathogenetic aspects, autoimmunity and pharmacotherapy in coronavirus infection (COVID-19) and immunoinflammatory rheumatic diseases
by: K. S. Rutskaya-Moroshan, et al.
Published: (2022-10-01) -
Course and outcomes of COVID-19 in patients with immunoinflammatory rheumatic diseases: Preliminary data from the NIIR/APP-COVID-19 registry and literature review
by: E. L. Nasonov, et al.
Published: (2021-12-01)